Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir

Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir

Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis. We encountered a patient exhibiting severe hyperbilirubine...

Full description

Bibliographic Details
Main Authors: Hayato Baba, Kazuto Tajiri, Kohei Nagata, Kengo Kawai, Masami Minemura, Toshiro Sugiyama
Format: Article
Language:English
Published: Karger Publishers 2016-07-01
Series:Case Reports in Gastroenterology
Subjects:
Cirrhosis
Direct-acting agent
Hepatitis C virus
P-glycoprotein
Hyperbilirubinemia
Online Access:http://www.karger.com/Article/FullText/447486

Internet

http://www.karger.com/Article/FullText/447486

Similar Items